Novel Treatment Approaches for Patients with Multiple Myeloma |
| |
| Affiliation: | 1. Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany;2. Center for Primary Health Care Research, Lund University, Malmö, Sweden;3. Stanford Prevention Research Center, Stanford University School of Medicine, Stanford, CA, USA;4. Cancer Gene Therapy Group, Faculty of Medicine, University of Helsinki, Helsinki, Finland;5. Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland;1. School of Environmental Sciences, University of Guelph, 50 Stone Road East, Guelph, ON, Canada N1G 2W1;2. Vineland Research and Innovation Centre, 4890 Victoria Avenue North, Box 4000, Vineland Station, ON, Canada L0R 2E0;1. Department of Emergency Medicine, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China;2. Department of Oncology, Hangzhou Hospital of Traditional Chinese Medicine, Guangxing Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Province, China;3. Max-Planck Institute of Biochemistry, 82152 Martinsried;4. Institute of Immunology, University of Heidelberg, 69120 Heidelberg, Germany |
| |
| Abstract: | Treatment options for patients with multiple myeloma are a rapidly progressing area of clinical and scientific development. The discovery of key signaling pathways needed for myeloma cell growth and proliferation has resulted in a plethora of new and different treatment options. Chief among these new agents are the proteasome inhibitor bortezomib and the immunomodulatory agents thalidomide and lenalidomide. Efficacy for these agents has been extensively studied in the relapsed and refractory states, and more recently in induction therapy. Impressive responses have been observed in the induction and relapsed disease states, completely changing the disease treatment paradigms. Building on these successes and strong preclinical work, other signal transduction inhibitors are being tested in phase I and phase II clinical trials. These include agents that target histone acetylation, farnesylation, heat shock proteins, and direct AKT-targeting agents. Additionally, monoclonal antibody targets are being developed in an effort to target the tumor cells extracellularly. Clinical trial development based on preclinically designed rational combinations and targets have the potential to rapidly translate these findings into meaningful clinical responses. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
